Literature DB >> 9610741

Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.

R Nishimura1, K Moriyama, K Yasukawa, G R Mundy, T Yoneda.   

Abstract

Studies on the role of interleukin-6 (IL-6) in bone metabolism have been accumulating. However, its effects on osteoblasts are still unclear because the results are conflicting depending on the study models employed. We reasoned that these conflicting data are due to variable expression levels of membrane-bound IL-6 receptors (IL-6Rs). In the present study, we found that IL-6 in combination with soluble IL-6R (sIL-6R) consistently caused a marked elevation of alkaline phosphatase and a decrease in proliferation in the human osteoblastic cell line MG-63, which expressed no detectable membrane-bound IL-6R and failed to respond to IL-6. These effects of IL-6/sIL-6R were blocked by neutralizing antibodies to the IL-6 signal transducer gp130, suggesting an involvement of IL-6 signaling in the elicitation of the effects of IL-6/sIL-6R. Upon stimulation with IL-6/sIL-6R, the gp130, cytoplasmic Janus kinases JAK1 and JAK2 were tyrosine phosphorylated. Moreover, signal transducers and activators of transcription STAT1 and STAT3 were also tyrosine phosphorylated, translocated to the nucleus, and bound to the putative STAT-binding DNA elements. In addition, mitogen-activated protein (MAP) kinase was also activated in response to IL-6/sIL-6R These data demonstrate that sIL-6R may enhance the responsiveness of MG-63 cells to IL-6. Thus, IL-6 in collaboration with sIL-6R may modulate differentiation and proliferation of osteoblastic cells, presumably by activating two distinct signaling pathways of JAK-STAT and MAP kinase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610741     DOI: 10.1359/jbmr.1998.13.5.777

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases.

Authors:  Toru Hiraga; Akira Myoui; Nobuyuki Hashimoto; Akira Sasaki; Kenji Hata; Yoshihiro Morita; Hideki Yoshikawa; Clifford J Rosen; Gregory R Mundy; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

2.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Chikahisa Higuchi; Makoto Hirao; Michio Okamoto; Kota Koizumi; Tokimitsu Morimoto; Hideki Yoshikawa; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

3.  Reducing iron accumulation: A potential approach for the prevention and treatment of postmenopausal osteoporosis.

Authors:  Bin Chen; Guang-Fei Li; Ying Shen; X I Huang; You-Jia Xu
Journal:  Exp Ther Med       Date:  2015-05-08       Impact factor: 2.447

4.  IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis.

Authors:  Narelle E McGregor; Melissa Murat; Jeevithan Elango; Ingrid J Poulton; Emma C Walker; Blessing Crimeen-Irwin; Patricia W M Ho; Jonathan H Gooi; T John Martin; Natalie A Sims
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

5.  The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone.

Authors:  Sun Wook Cho; Flavia Q Pirih; Amy J Koh; Megan Michalski; Matthew R Eber; Kathryn Ritchie; Benjamin Sinder; Seojin Oh; Saja A Al-Dujaili; JoonHo Lee; Ken Kozloff; Theodora Danciu; Thomas J Wronski; Laurie K McCauley
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

6.  Whole blood gene expression and interleukin-6 levels.

Authors:  Honghuang Lin; Roby Joehanes; Luke C Pilling; Josée Dupuis; Kathryn L Lunetta; Sai-Xia Ying; Emelia J Benjamin; Dena Hernandez; Andrew Singleton; David Melzer; Peter J Munson; Daniel Levy; Luigi Ferrucci; Joanne M Murabito
Journal:  Genomics       Date:  2014-10-13       Impact factor: 5.736

7.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

Authors:  Dhong Hyun Lee; Nils H Thoennissen; Catherine Goff; Gabriela B Iwanski; Charles Forscher; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Cancer Lett       Date:  2011-03-26       Impact factor: 8.679

8.  Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.

Authors:  Kanji Mori; Frederic Blanchard; Celine Charrier; Severine Battaglia; Kosei Ando; Laurence Duplomb; Leonard D Shultz; Francoise Redini; Dominique Heymann
Journal:  Cancer Sci       Date:  2008-10-18       Impact factor: 6.716

9.  Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways.

Authors:  Natalie A Sims; Brendan J Jenkins; Julian M W Quinn; Akira Nakamura; Markus Glatt; Matthew T Gillespie; Matthias Ernst; T John Martin
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

10.  Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation.

Authors:  Sadahiro Kamiya; Chika Nakamura; Takeshi Fukawa; Katsuhiro Ono; Toshiyuki Ohwaki; Takayuki Yoshimoto; Seiki Wada
Journal:  J Bone Miner Metab       Date:  2007-08-25       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.